Natick, MA-based Boston Scientific (NYSE: [[ticker:BSX]]) announced this morning that it will pay up to $240 million to cover 8,550 patient claims related to defibrillators from Guidant, which Boston Scientific acquired last year. This settlement is expanded from a $195 million agreement announced in July, and covers “substantially all currently asserted claims in the United States” related to a series of recalls and warnings on the Guidant devices.
Author: Rebecca Zacks
Rebecca is Xconomy's co-founder. She was previously the managing editor of Physician's First Watch, a daily e-newsletter from the publishers of New England Journal of Medicine. Before helping launch First Watch, she spent a decade covering innovation for Technology Review, Scientific American, and Discover Magazine's TV show. In 2005-2006 she was a Knight Science Journalism Fellow at MIT. Rebecca holds a bachelor's degree in biology from Brown University and a master's in science journalism from Boston University.
View all posts by Rebecca Zacks
